Xenon Pharmaceuticals Inc. financial data

Symbol
XENE on Nasdaq
Location
Burnaby
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1451% % -37%
Debt-to-equity 7.2% % 56%
Return On Equity -56% % -96%
Return On Assets -52% % -91%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 83,190,316 shares 8.7%
Common Stock, Shares, Outstanding 80,010,790 shares 4.7%
Entity Public Float $2,404,900,000 USD -18%
Common Stock, Value, Issued $1,598,571,000 USD 9.7%
Weighted Average Number of Shares Outstanding, Basic 79,253,751 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 79,253,751 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $300,938,000 USD 43%
General and Administrative Expense $79,632,000 USD 16%
Operating Income (Loss) $373,070,000 USD -34%
Nonoperating Income (Expense) $28,176,000 USD -31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $344,894,000 USD -45%
Income Tax Expense (Benefit) $1,016,000 USD
Net Income (Loss) Attributable to Parent $345,910,000 USD -48%
Earnings Per Share, Basic -4.36 USD/shares -45%
Earnings Per Share, Diluted -4.36 USD/shares -45%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $199,163,000 USD 40%
Marketable Securities, Current $349,723,000 USD -28%
Accounts Receivable, after Allowance for Credit Loss, Current $1,469,000 USD 68%
Assets, Current $560,649,000 USD -12%
Deferred Income Tax Assets, Net $12,864,000 USD 33%
Property, Plant and Equipment, Net $8,721,000 USD -15%
Operating Lease, Right-of-Use Asset $6,626,000 USD -17%
Assets $633,163,000 USD -21%
Employee-related Liabilities, Current $14,460,000 USD 46%
Liabilities, Current $41,792,000 USD 17%
Operating Lease, Liability, Noncurrent $6,412,000 USD -16%
Other Liabilities, Noncurrent $3,199,000 USD
Liabilities $51,403,000 USD 19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $335,000 USD
Retained Earnings (Accumulated Deficit) $1,245,380,000 USD -38%
Stockholders' Equity Attributable to Parent $581,760,000 USD -23%
Liabilities and Equity $633,163,000 USD -21%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $61,652,000 USD -33%
Net Cash Provided by (Used in) Financing Activities $1,151,000 USD
Net Cash Provided by (Used in) Investing Activities $34,510,000 USD
Common Stock, Shares, Issued 80,010,790 shares 4.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $26,055,000 USD 71%
Deferred Tax Assets, Valuation Allowance $346,794,000 USD 30%
Deferred Tax Assets, Gross $361,372,000 USD 30%
Operating Lease, Liability $7,944,000 USD -12%
Payments to Acquire Property, Plant, and Equipment $43,000 USD -77%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $343,963,000 USD -46%
Lessee, Operating Lease, Liability, to be Paid $8,811,000 USD -13%
Operating Lease, Liability, Current $1,532,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,788,000 USD 1.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $1,801,000 USD 6.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.037 pure -2.6%
Deferred Income Tax Expense (Benefit) $1,213,000 USD -401%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $867,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid, Year Three $1,087,000 USD -37%
Deferred Tax Assets, Operating Loss Carryforwards $251,701,000 USD 45%
Unrecognized Tax Benefits $13,301,000 USD 23%
Lessee, Operating Lease, Liability, to be Paid, Year Four $1,137,000 USD 9.6%
Operating Lease, Payments $420,000 USD 2.2%
Deferred Tax Assets, Net of Valuation Allowance $14,578,000 USD 24%
Share-based Payment Arrangement, Expense $53,707,000 USD 5.9%